

Trust Headquarters  
Russells Hall Hospital  
Dudley  
West Midlands  
DY1 2HQ

**Ref:** FOI-112024-0001259

**Date:** 6.5.25

**Address / Email:**

Dear

**Request Under Freedom of Information Act 2000**

Thank you for requesting information under the Freedom of Information Act 2000.

Under the Freedom of Information Act, I would like to request the following information:

1. For the financial years 2022/23, 2023/24 and current YTD, how many referrals have you received for wet AMD, diabetic macular oedema and retinal vein occlusion (Anti VEGf services) or perhaps referred to as medical retina?
2. For the financial years 2022/23, 2023/24 and current YTD, how many referrals have you rejected as unsuitable or undeliverable by your Trust?
3. For the financial years 2022/23, 2023/24 and current YTD, how many referrals have you received, triaged, booked and completed first assessment and treatment within the 2 week RTT advised by NICE and the college of ophthalmologists? We are looking for your Trust performance data against the 14 day standard as a % by month for the periods - 2023/24 and 2024/25
4. How many patients are currently on a waiting list for an appointment for first assessment and or treatment ? How many have breached the 2 week RTT? –
5. How many patients are currently on a waiting list for a follow up appointment and treatment? How many of these have waited longer than the requested call back date stated as an outcome of their last assessment? (Ie overdue?) How many are overdue by more than one month? (We exclude from this any patients who have cancelled / DNA'd or are unable to attend an appointment that has been offered)

**Questions 1 to 5 please see attached spreadsheet**

**For a copy of the spreadsheet please contact [dqft.foi@nhs.net](mailto:dqft.foi@nhs.net) quoting reference number FOI-112024-0001259**

6. Which drugs are your preferred for a new patient? Which drugs do you still use for follow-up patients?

**For new patients with wet ARMD , we use FARICIMAB ( VABYSMO).**

**For new patients with DMO, we use FARICIMAB, EYLEA and occasionally OZURDEX**

**For new patients with vein occlusion, we use OZURDEX and sometimes VABYSMO**

**For follow-up patient with wet ARMD, we use FARICIMAB, ONGAVIA ( Ranibizumab Bio-similar) depending on what drug they have been using before.**

For follow-up patients with DMO, we use EYLEA, FARICIMAB, OZURDEX depending on the response of the patient and what drug they were using before.  
For follow-up patients with vein occlusion, we use OZURDEX and sometimes VABYSMO, Ranibizumab Biosimilar depending on what drug patient has been using before and if there are any contra-indications for a particular drug.

7.Does your trust follow a see and treat "one stop" clinic format? - **No**

8.Does your trust follow treat and extend protocols where clinically appropriate? - **The injection and clinic review are booked accordingly to treat and extend protocol where clinically appropriate.**

9.How many patients have you certificated as sight impaired or severely sight impaired in the FYs 2022/23, 2023/24 and year to date due to Wet AMD? - **We do not record this data**

If you are dissatisfied with our response, you have the right to appeal in line with guidance from the Information Commissioner. In the first instance you may contact the Information Governance Manager of the Trust.

Information Governance Manager  
Trust Headquarters  
Russell's Hall Hospital  
Dudley  
West Midlands  
DY1 2HQ  
Email: [dgft.dpo@nhs.net](mailto:dgft.dpo@nhs.net)

Should you disagree with the contents of our response to your appeal, you have the right to appeal to the Information Commissioners Office at.

Information Commissioners Office  
Wycliffe House  
Water Lane  
Wilmslow  
Cheshire  
SK9 5AF  
Tel: 0303 123 1113  
[www.ico.org.uk](http://www.ico.org.uk)

If you require further clarification, please do not hesitate to contact us.

Yours sincerely

**Freedom of Information Team  
The Dudley Group NHS Foundation Trust**